The CSL Behring Commitment

CSL Behring offers many programs and services to the bleeding disorders community, in addition to its range of blood products. Check out this wide variety of resources:

Reimbursement Resources Center
Call 1-800-676-4266 for expert advice and information about insurance matters, including health insurance reimbursement for CSL Behring products.

Patient Assistance Program
This program provides medically necessary therapies to qualified patients who are uninsured, underinsured, or who cannot afford their prescribed therapy.

CSL Behring Assurance^SM
A lapse in insurance coverage can happen—and it can be scary. CSL Behring Assurance^SM helps people who rely on Humate-P^® to continue to receive treatment during a lapse in third-party private health insurance.

Project Red Flag
Project Red Flag (PRF) is a campaign by the National Hemophilia Foundation aimed at educating women and their healthcare providers about the symptoms, diagnosis, and treatment of bleeding disorders.CSL Behring proudly supports PRF, along with the Centers for Disease Control and Prevention.

Gettin’ in the Game ^SM
Gettin’ in the Game was started by CSL Behring to encourage kids with bleeding disorders to be physically active. Children and their families can get sports tips from professional athletes, participate in exercises or sports competitions, and meet other kids with bleeding disorders.

VWD Consumer Advisory Committee
CSL Behring hosts meetings with VWD patients and parents to keep current on the needs and interests of the VWD community, and to provide a forum for consumers to exchange ideas.

CSL Behring Junior National Championships
A fun-filled annual golf and baseball competition for children ages 7 through 18.

For more information about programs and services offered by CSL Behring, call our Consumer Affairs Center at 1-888-508-6978.

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.